173 related articles for article (PubMed ID: 19953878)
21. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil.
Barkmann A; Nashan B; Schmidt HH; Böker KH; Emmanouilidis N; Rosenau J; Bahr MJ; Hoffmann MW; Manns MP; Klempnauer J; Schlitt HJ
Transplantation; 2000 May; 69(9):1886-90. PubMed ID: 10830227
[TBL] [Abstract][Full Text] [Related]
22. Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.
Kornberg A; Küpper B; Thrum K; Krause B; Büchler P; Kornberg J; Sappler A; Altendorf-Hofmann A; Wilberg J; Friess H
Dig Dis Sci; 2011 Jan; 56(1):244-51. PubMed ID: 20824504
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction.
Cantarovich M; Tzimas GN; Barkun J; Deschênes M; Alpert E; Tchervenkov J
Transplantation; 2003 Jul; 76(1):98-102. PubMed ID: 12865793
[TBL] [Abstract][Full Text] [Related]
24. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study.
Beckebaum S; Klein CG; Sotiropoulos GC; Saner FH; Gerken G; Paul A; Cicinnati VR
Transplant Proc; 2009; 41(6):2567-9. PubMed ID: 19715976
[TBL] [Abstract][Full Text] [Related]
25. Introduction of mycophenolate mofetil in maintenance liver transplant recipients: what can we expect? Results of a 10-year experience.
Dumortier J; Guillaud O; Pittau G; Salandre J; Adham M; Scoazec JY; Boillot O
Transplant Proc; 2010 Sep; 42(7):2602-6. PubMed ID: 20832553
[TBL] [Abstract][Full Text] [Related]
26. Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis.
Zahn A; Müeller F; Hinz U; Schemmer P; Stremmel W; Ganten T
Ann Transplant; 2013 Oct; 18():525-32. PubMed ID: 24088725
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
[TBL] [Abstract][Full Text] [Related]
28. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
[TBL] [Abstract][Full Text] [Related]
30. Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor.
Eisenberger U; Sollinger D; Stickel F; Burckhardt B; Frey FJ
Clin Transplant; 2009; 23(4):499-504. PubMed ID: 19486346
[TBL] [Abstract][Full Text] [Related]
31. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
[TBL] [Abstract][Full Text] [Related]
32. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant.
Biselli M; Vitale G; Gramenzi A; Riili A; Berardi S; Cammà C; Scuteri A; Morelli MC; Grazi GL; Pinna AD; Andreone P; Bernardi M
Clin Transplant; 2009; 23(2):191-8. PubMed ID: 19210525
[TBL] [Abstract][Full Text] [Related]
33. A non-induction renal sparing approach after liver transplantation: high dose mycophenolate mofetil with delayed, low-dose tacrolimus.
Rao V; Haywood S; Abecassis M; Levitsky J
Transplant Proc; 2013; 45(1):320-2. PubMed ID: 23267806
[TBL] [Abstract][Full Text] [Related]
34. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
[TBL] [Abstract][Full Text] [Related]
35. Calcineurin-inhibitor-sparing immunosuppressive protocols.
Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
[TBL] [Abstract][Full Text] [Related]
36. Mycophenolate mofetil monotherapy in liver transplant recipients.
Kriss M; Sotil EU; Abecassis M; Welti M; Levitsky J
Clin Transplant; 2011; 25(6):E639-46. PubMed ID: 22007615
[TBL] [Abstract][Full Text] [Related]
37. The renal benefit of mycophenolate mofetil after liver transplantation.
Haywood S; Abecassis M; Levitsky J
Clin Transplant; 2011; 25(1):E88-95. PubMed ID: 21070365
[TBL] [Abstract][Full Text] [Related]
38. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
Leiskau C; Rajanayagam J; Pfister ED; Goldschmidt I; Junge N; Karch A; Lerch C; Richter N; Lehner F; Schrem H; Baumann U
Pediatr Transplant; 2018 Aug; 22(5):e13207. PubMed ID: 29729061
[TBL] [Abstract][Full Text] [Related]
39. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications.
Miras M; Carballo F; Egea J; Martínez C; Alvarez-López MR; Sánchez-Bueno F; Parrilla P
Transplant Proc; 2007 Sep; 39(7):2314-7. PubMed ID: 17889175
[TBL] [Abstract][Full Text] [Related]
40. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients.
Mourer JS; Ewe SH; Mallat MJ; Ng AC; Rabelink TJ; Bax JJ; Delgado V; de Fijter JW
Transplantation; 2012 Oct; 94(7):721-8. PubMed ID: 22955227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
